D. Howard

发表

On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development

R. Sarangapani, P. Lowe, Y. Hijazi, 2007, Xenobiotica; the fate of foreign compounds in biological systems.

Effects of Aliskiren, a Direct Renin Inhibitor, on Cardiac Repolarization and Conduction in Healthy Subjects

S. Vaidyanathan, W. Dole, D. Howard, 2008, Journal of clinical pharmacology.

Pharmacokinetic and pharmacodynamic properties of canakinumab in patients with gouty arthritis

G. Sunkara, A. Chakraborty, D. Howard, 2013, Journal of clinical pharmacology.

Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects*

S. Leon, Yan-Ling He, G. Sunkara, 2007, Current medical research and opinion.

A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects*

S. Vaidyanathan, W. Dole, D. Howard, 2008, Current medical research and opinion.

Pharmacokinetics of the active metabolite (MDL 74,156) of dolasetron mesylate after oral or intravenous administration to anesthetized children

J. Lerman, N. Sikich, D. Howard, 1996, Clinical pharmacology and therapeutics.

Pharmacokinetics, Safety, and Tolerability of the Novel Oral Direct Renin Inhibitor Aliskiren in Elderly Healthy Subjects

C. Reynolds, S. Vaidyanathan, M. Bizot, 2007, Journal of clinical pharmacology.

Pharmacokinetics of the Oral Direct Renin Inhibitor Aliskiren Alone and in Combination with Irbesartan in Renal Impairment

S. Vaidyanathan, M. Bizot, W. Dole, 2007, Clinical pharmacokinetics.

Vildagliptin, a Novel Dipeptidyl Peptidase IV Inhibitor, Has No Pharmacokinetic Interactions With the Antihypertensive Agents Amlodipine, Valsartan, and Ramipril in Healthy Subjects

Yan-Ling He, G. Sunkara, M. Ligueros-Saylan, 2008, Journal of clinical pharmacology.

Practical Considerations for Clinical Pharmacology in Drug Development: A Survey of 44 FDA Oncology Approvals

D. Howard, 2016 .

The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin

Yan-Ling He, K. Lasseter, W. Dole, 2007, European Journal of Clinical Pharmacology.

The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers.

Yan-Ling He, W. Dole, R. Sabo, 2008, British journal of clinical pharmacology.

Dose Proportionality and the Effect of Food on Vildagliptin, a Novel Dipeptidyl Peptidase IV Inhibitor, in Healthy Volunteers

Yan-Ling He, G. Sunkara, W. Dole, 2007, Journal of clinical pharmacology.

A Randomized, Crossover Study to Evaluate the Pharmacokinetics of Amantadine and Oseltamivir Administered Alone and in Combination

C. Rayner, T. Evans, D. Howard, 2007, PloS one.

Disposition of Vildagliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, in Rats and Dogs

V. Fischer, D. Howard, H. Yin, 2009, Drug Metabolism and Disposition.

The Absolute Oral Bioavailability and Population-Based Pharmacokinetic Modelling of a Novel Dipeptidylpeptidase-IV Inhibitor, Vildagliptin, in Healthy Volunteers

Yan-Ling He, B. Sadler, R. Sabo, 2007, Clinical pharmacokinetics.

Influence of Body Weight and Gender on the Pharmacokinetics, Pharmacodynamics, and Antihypertensive Efficacy of Aliskiren

W. Dole, D. Howard, C. Yeh, 2010, Journal of clinical pharmacology.

Pharmacokinetic interaction of the direct renin inhibitor aliskiren with furosemide and extended-release isosorbide-5-mononitrate in healthy subjects.

S. Vaidyanathan, W. Dole, D. Howard, 2008, Cardiovascular therapeutics.

Effect of aliskiren, an oral direct renin inhibitor, on the pharmacokinetics and pharmacodynamics of a single dose of acenocoumarol in healthy volunteers*

S. Vaidyanathan, M. Bizot, W. Dole, 2008, Current medical research and opinion.

Acetylcholinesterase inhibition by zifrosilone: Pharmacokinetics and pharmacodynamics

N. Cutler, E. Brass, A. Barchowsky, 1995, Clinical pharmacology and therapeutics.

Open-label comparison of the antiemetic efficacy of single intravenous doses of dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy.

Mark L. Greenberg, M. Coppes, R. Barr, 1999, Medical and pediatric oncology.

Safety, tolerability, antiemetic efficacy, and pharmacokinetics of oral dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy.

M. Coppes, C. Pratt, D. Howard, 1999, Journal of pediatric hematology/oncology.

A study of dose-proportionality in the pharmacokinetics of the oral direct renin inhibitor aliskiren in healthy subjects.

S. Vaidyanathan, W. Dole, D. Limoges, 2008, International journal of clinical pharmacology and therapeutics.

The safety, tolerability, pharmacokinetics, and pharmacodynamics of a selective 5-HT2A antagonist, M100907, following single and multiple oral dosing in healthy volunteers

D. Howard, F. Brunner, S. Offord, 1998, European Neuropsychopharmacology.

Pharmacokinetics of the Oral Direct Renin Inhibitor Aliskiren in Combination With Digoxin, Atorvastatin, and Ketoconazole in Healthy Subjects: The Role of P‐Glycoprotein in the Disposition of Aliskiren

C. Reynolds, S. Vaidyanathan, M. Bizot, 2008, Journal of clinical pharmacology.

Clinical pharmacology and pharmacogenetics of thiopurines

S. Sahasranaman, D. Howard, Sandip K. Roy, 2008, European Journal of Clinical Pharmacology.

The Use of Dried Blood Spots for Concentration Assessment in Pharmacokinetic Evaluations

D. Howard, T. Majumdar, 2011 .

Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trial

E. Clay, M. Toumi, D. Malka, 2022, BMJ Open.

Absorption, Metabolism, and Excretion of [14C]Vildagliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, in Humans

V. Fischer, J. Mangold, D. Howard, 2009, Drug Metabolism and Disposition.

A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with allopurinol, celecoxib and cimetidine in healthy subjects

M. Bizot, W. Dole, D. Howard, 2008, Current medical research and opinion.

Pharmacodynamic Analysis of the Microbiological Efficacy of Telithromycin in Patients with Community-Acquired Pneumonia

J. Barrett, R. Port, S. Jenkins, 2005, Clinical pharmacokinetics.

S. Vaidyanathan, W. Dole, D. Howard, 2008 .

Evaluation of Pharmacokinetic Interactions Between Vildagliptin and Digoxin in Healthy Volunteers

S. Leon, Yan-Ling He, G. Sunkara, 2007, Journal of clinical pharmacology.

Clinical Pharmacokinetics and Pharmacodynamics of Aliskiren

S. Vaidyanathan, W. Dole, D. Howard, 2008, Clinical pharmacokinetics.

Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of Aliskiren in Healthy Chinese Subjects

Shuyang Zhang, Ji Jiang, P. Hu, 2010, Clinical drug investigation.

Single-dose and steady-state bioequivalence of fexofenadine and pseudoephedrine combination tablets compared with individual formulations in healthy adults

D. Howard, B. Kittner, P. Agrawala, 2005, Current Medical Research and Opinion.

A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with allopurinol, celecoxib and cimetidine in healthy subjects

M. Bizot, W. Dole, D. Howard, 2008 .